Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
深入研究Biomarin製藥股票：分析師觀點（8個評級）
In the preceding three months, 8 analysts have released ratings for Biomarin Pharmaceutical (NASDAQ:BMRN), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，有8位分析師發佈了Biomarin Pharmaceutical（納斯達克股票代碼：BMRN）的評級，提出了從看漲到看跌的各種觀點。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表簡要概述了分析師最近的評級，提供了對過去30天情緒變化的見解，並與前幾個月進行了比較以獲得整體視角。
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $100.88, a high estimate of $110.00, and a low estimate of $85.00. This current average has decreased by 5.05% from the previous average price target of $106.25.
分析師爲Biomarin Pharmaceutical設定了12個月的目標股價，顯示平均目標股價爲100.88美元，最高估計爲110.00美元，低估值爲85.00美元。目前的平均價格較之前的平均目標價106.25美元下降了5.05％。
Exploring Analyst Ratings: An In-Depth Overview...
探索分析師評級...
登入免費觀看全文
登入/註冊